Abbott Laboratories (ABT)
| Market Cap | 224.76B |
| Revenue (ttm) | 43.11B |
| Net Income (ttm) | 13.93B |
| Shares Out | 1.74B |
| EPS (ttm) | 7.97 |
| PE Ratio | 16.18 |
| Forward PE | 23.86 |
| Dividend | $2.36 (1.83%) |
| Ex-Dividend Date | Jul 15, 2025 |
| Volume | 2,421,285 |
| Open | 131.12 |
| Previous Close | 131.02 |
| Day's Range | 128.33 - 131.65 |
| 52-Week Range | 107.60 - 141.23 |
| Beta | 0.70 |
| Analysts | Strong Buy |
| Price Target | 142.79 (+10.57%) |
| Earnings Date | Jul 17, 2025 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for ABT stock is "Strong Buy." The 12-month stock price target is $142.79, which is an increase of 10.57% from the latest price.
News
Abbott India's profit climbs on healthy pharmaceutical demand
Drugmaker Abbott India reported an 11.5% rise in first-quarter profit on Tuesday, driven by healthy sales in its mainstay pharmaceuticals segment.
Abbott Laboratories Q2 Earnings: Dividends Don't Lie
Abbott's Q2 performance reflects some evenness and the potential headwinds from macroeconomic uncertainties. However, short-term issues like tariffs and drug price control do not fundamentally alter A...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Best Dividend Aristocrats For August 2025
Dividend Aristocrats are outperforming SPY in July but still trail year-to-date; select Aristocrats delivered double-digit gains and strong dividend growth. 47 of 69 Aristocrats raised dividends in 20...
Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...
Best Dividend Kings: July 2025
14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently a...
These Analysts Revise Their Forecasts On Abbott Following Q2 Results
Abbott Laboratories ABT reported better-than-expected sales and profits in the second quarter, but dialed back earnings and growth projections for the rest of the year.
Abbott Laboratories: What's Behind The Q2 Earnings Slump?
ABT, which had been outperforming the healthcare cohort from the S&P 500 and the S&P 500 itself all through this year, has slumped dramatically following yesterday's Q2 earnings. While Q2 sales beat e...
Abbott CEO Robert Ford goes one-on-one with Jim Cramer
Abbott Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk quarterly results, lowering its full-year guidance, sale trends, and more.
Didn't see the recovery in China we were expecting, says Abbott Labs CEO on lowering guidance
Abbott Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk quarterly results, lowering its full-year guidance, sale trends, and more.
Abbott Laboratories CEO calls post-earnings stock decline 'a little bit of an overreaction'
Abbott Laboratories CEO Robert Ford unpacked his company's latest quarterly report in a Thursday interview with CNBC's Jim Cramer, saying that Wall Street's reaction to the results was too extreme. "I...
Abbott Laboratories (ABT) Q2 2025 Earnings Call Transcript
Abbott Laboratories (NYSE:ABT) Q2 2025 Results Conference Call July 17, 2025 9:00 AM ET Company Participants Michael Comilla - Vice President of Investor Relations. Philip P. Boudreau - CFO & Executi...
Abbott Laboratories Issues Weak Earnings Forecast, Joins MP Materials And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.2% on Thursday.
Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares.
Abbott Laboratories stock falls even as the company reports second-quarter sales that top expectations.
Abbott beats quarterly profit estimates on medical devices demand
Abbott beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its medical devices including continuous glucose monitors.
Abbott Reports Second-Quarter 2025 Results
Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1 Second-quarter GAAP diluted EPS of $1.01; adjusted dil...
Abbott Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Abbott Laboratories ABT will release earnings results for the second quarter, before the opening bell on Thursday, July 17.
Sell ABT Stock Ahead Of Its Q2 Earnings?
Abbott Laboratories (NYSE:ABT) is scheduled to announce its second-quarter earnings on Thursday, July 17, 2025. For traders who focus on events, examining the historical reactions of the stock to earn...
Should You Buy Abbott Stock At $135?
Abbott Laboratories (NYSE:ABT) has greatly exceeded the broader S&P 500 index this year, with its stock price increasing by 18% compared to the S&P 500's 6% rise. This strong performance is due to the...
Abbott Labs: Proactive, Adaptive, Solid
Abbott's proactive leadership and diversified business model help it navigate macro challenges and market volatility effectively. Strong Q1 performance in Nutrition, Medical Devices, and Vascular segm...
Abbott Laboratories: FreeStyle Libre CGMs And EPD Business Driving Positive Momentum
Key collaborations enable Abbott to increase its global presence and accessibility to patients who haven't used CGMs before, potentially resulting in a 15% CAGR in FreeStyle Libre sales by 2028. With ...
Best Dividend Aristocrats For July 2025
Dividend Aristocrats have underperformed the S&P 500 in 2025, with NOBL up 1.77% versus SPY's 5.55% year-to-date gain. Dividend growth remains healthy, with 44 out of 69 Aristocrats already raising pa...
Abbott Hosts Conference Call for Second-Quarter Earnings
ABBOTT PARK, Ill., June 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2025 financial results on Thursday, July 17, before the market opens.
